Cáncer gástrico: una enfermedad prevenible. Estrategias para intervención en la historia natural
DOI:
https://doi.org/10.22516/25007440.394Keywords:
Gastric cacer, helicobacter pylori, prevention, natural historyAbstract
Gastric cancer is a public health problem, but there are no usable mortality and survival statistics for Colombia. The country has no early diagnosis program or strategy, and gastric cancer is not prioritized as a health problem. Existing studies show that most patients are in advanced stages by the time they are diagnosed.
Ninety percent of gastric cancers are considered to be consequences of long inflammatory processes in the gastric mucosa. H Pylori infections are the most common etiology of gastritis which can progress to atrophy, metaplasia, dysplasia and cancer. Gastric atrophy establishes a cancerization field which is prone to molecular and phenotypic changes that end in cancerous growth. It is well understood that a disease’s natural history provides a rational pathological clinical understanding for primary and secondary prevention strategies. Well-established evidence shows that the combination of primary (H pylori eradication) and secondary strategies (diagnosis and endoscopic follow-up of pre-malignant lesions) can prevent or limit the progression of gastric carcinogenesis. The risk of gastric cancer associated with H pylori gastritis can be stratified according to the severity and extent of atrophy of the gastric mucosa. This approach has been adapted to many different countries according to specific incidences of gastric cancer, socio-economic conditions and cultural factors. This requires the complementary participation of gastroenterologists, surgeons, oncologists and pathologists.
In the face of this public health problem, there has been no action by health authorities or the medical association. For this reason, we have reviewed management strategies that allow intervening into the natural history of the disease to reduce its incidence and mortality rate.
The implementation and standardization of these management strategies in our environment may benefit patients who are at high risk for gastric cancer. These strategies can be implemented in a rational way, similar to what is being done with rectal cancer, in countries without screening programs all over the world.
Downloads
References
Den Hoed C, Kuipers E. Gastric Cancer: How can we reduce the incidence of this Disease? Curr Gastroenterol Rep. 2016;18(34):1-8. https://doi.org/10.1007/s11894-016-0506-0.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cáncer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492.
Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc. 2014;47(6):478-89. https://doi.org/10.5946/ce.2014.47.6.478.
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354-62. https://doi.org/10.3748/wjg.v12.i3.354.
World Health Organization. GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018. Colombia. WHO [internet] 2018 [acceso 12 de septiembre del 2018]. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf.
Piazuelo M, Correa P. Gastric cancer: overview. Colomb Med. 2013;44(3):192-201.
Gómez M, Riveros J, Ruiz O, Concha A, Ángel D, Torres M, et al. Guía de práctica clínica para la prevención diagnóstico y tratamiento del cáncer gástrico temprano 2015. Rev Col Gastroenterol. 2015; 30 supl 1:34-42.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-7. https://doi.org/10.1016/j.gtc.2013.01.002.
Choi IJ. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc. 2014;47(6):497-503. https://doi.org/10.5946/ce.2014.47.6.497.
Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786-808. https://doi.org/10.3748/wjg.v20.i22.6786.
Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY. Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations. Gut Liver. 2016;10(1):12-26. https://doi.org/10.5009/gnl15091.
Moss SF. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cell Mol Gastroenterol Hepatol. 2016;3(2):183-91. https://doi.org/10.1016/j.jcmgh.2016.12.001.
Archila P, Tovar L, Ruiz M. Características histológicas de la gastritis crónica reportadas en las biopsias gástricas de niños de 1 a 16 años de edad en el Hospital Infantil de San José durante el periodo comprendido entre septiembre de 2008 a septiembre de 2010. Rev Col Gastroenterol. 2012;27(2):74-9.
Bedoya A, Sansón F, Yepes Y, Santacruz C, Cifuentes Y, Calvache D, et al. Prevalencia y severidad de las lesiones precursoras de malignidad en un área de alto riesgo de cáncer gástrico. Pasto 2012. Rev Col Gastroenterol. 2012;27(4):275-81.
González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130(4):745-53. https://doi.org/10.1002/ijc.26430.
Yaghoobi M, McNabb-Baltar J, Bijarchi R, Hunt RH. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis. World J Gastroenterol. 2017;23(13):2435-42. https://doi.org/10.3748/wjg.v23.i13.2435.
Yoon H, Kim N. Diagnosis and management of high risk group for gastric cancer. Gut Liver. 2015;9(1):5-17. https://doi.org/10.5009/gnl14118.
Sugimoto M, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, et al. Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer. Intern Med. 2017;56(6):579-86. https://doi.org/10.2169/internalmedicine.56.7775.
Leja M, You W, Camargo MC, Saito H. Implementation of gastric cancer screening - the global experience. Best Pract Res Clin Gastroenterol. 2014;28(6):1093-106. https://doi.org/10.1016/j.bpg.2014.09.005.
Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. https://doi.org/10.1136/bmj.g3174.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. https://doi.org/10.1136/gutjnl-2015-309252.
Wroblewski LE, Peek RM Jr. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am. 2013;42(2):285-98. https://doi.org/10.1016/j.gtc.2013.01.006.
Graham DY, Uemura N. Natural history of gastric cancer after Helicobacter pylori eradication in Japan: after endoscopic resection, after treatment of the general population, and naturally. Helicobacter. 2006;11(3):139-43. 10.1111/j.1523-5378.2006.00391.x.
Rugge M. Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication. Gastroenterol Clin North Am. 2015;44(3):609-24. https://doi.org/10.1016/j.gtc.2015.05.009.
Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392-7. https://doi.org/10.1016/S0140-6736(08)61159-9.
Grisales P. No hay enemigo pequeño: avances contra helicobacter pylori. Pesquisa. 2017;40:14-6.
Coelho LG, Maguinilk I, Zaterka S, Parente JM, do Carmo Friche Passos M, Moraes-Filho JP. 3rd Brazilian Consensus on Helicobacter pylori. Arq Gastroenterol. 2013 Apr;50(2). pii: S0004-28032013005000113. https://doi.org/10.1590/S0004-28032013005000001.
Rollán A, Cortés P, Calvo A, Araya R, Bufadel ME, González R, et al. Recommendations of the Chilean Association for Digestive Endoscopy for the management of gastric pre-malignant lesions. Rev Med Chil. 2014;142(9):1181-92. https://doi.org/10.4067/S0034-98872014000900013.
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150(5):1113-24.e5. https://doi.org/10.1053/j.gastro.2016.01.028.
Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013;132(6):1272-6. https://doi.org/10.1002/ijc.27965.
Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis. 2017;17(1):156. https://doi.org/10.1186/s12879-017-2259-2.
Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27(6):933-47. https://doi.org/10.1016/j.bpg.2013.09.005.
Rollan A, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P. Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol. 2006;12(44):7172-8. https://doi.org/10.3748/wjg.v12.i44.7172.
Oliveros R, Navarra LF. Diagnóstico, estadificación y tratamiento del cáncer gástrico en Colombia desde 2004 a 2008 (Regate- Colombia). Rev Col Gastroenterol. 2012;27(4):269-74.
Correa P, Haenszel W, Cuello C, Zabala D, Fontham E, Zarama G, et al. The gastric precursors in a high risk population: cross-sectional studies. Cancer Res. 1990;50:1731-6.
den Hoed CM, Holster IL, Capelle LG, de Vries AC, den Hartog B, Ter Borg F, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy. 2013;45(4):249-56. https://doi.org/10.1055/s-0032-1326379.
Zullo A, Hassan C, Repici A, Annibale B. Intestinal metaplasia surveillance: searching for the road-map. World J Gastroenterol. 2013;19(10):1523-6. https://doi.org/10.3748/wjg.v19.i10.1523.
Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43 Suppl 4:S373-84. https://doi.org/10.1016/S1590-8658(11)60593-8.
Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74-94. https://doi.org/10.1055/s-0031-1291491.
Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015;20(1):25-40. https://doi.org/10.15430/JCP.2015.20.1.25.
Lage J, Uedo N, Dinis-Ribeiro M, Yao K. Surveillance of patients with gastric precancerous conditions. Best Pract Res Clin Gastroenterol. 2016;30(6):913-22. https://doi.org/10.1016/j.bpg.2016.09.004.
ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82(1):1-8. https://doi.org/10.1016/j.gie.2015.03.1967.
Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105(3):493-8. https://doi.org/10.1038/ajg.2009.728.
Cañadas R. Metaplasia intestinal gástrica: ¿cómo la estamos abordando? Rev Col Gastroenterol. 2012;27(4):259-62.
Martinez D, Otero W, Ricaurte O. Impacto del sistema OLGA en la detección de gastritis crónica atrófica en Colombia: un estudio de casos y controles. Rev Col Gastroenterol. 2016;31(4)360-7. https://doi.org/10.22516/25007440.111.
Pittayanon R, Rerknimitr R, Klaikaew N, Sanpavat A, Chaithongrat S, Mahachai V, et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther. 2017;46(1):40-45. https://doi.org/10.1111/apt.14082.
Sung JK. Diagnosis and management of gastric dysplasia. Korean J Intern Med. 2016;31(2):201-9. https://doi.org/10.3904/kjim.2016.021.
Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, et al. Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative. United European Gastroenterol J. 2016;4(5):629-656. https://doi.org/10.1177/2050640616664843.
Iwai T, Yoshida M, Ono H, Kakushima N, Takizawa K, Tanaka M, et al. Natural History of Early Gastric Cancer: a Case Report and Literature Review. J Gastric Cancer. 2017;17(1):88-92. https://doi.org/10.5230/jgc.2017.17.e9.
de Vries E, Uribe C, Pardo C, Lemmens V, Van de Poel E, Forman D. Gastric cancer survival and affiliation to health insurance in a middle-income setting. Cancer Epidemiol. 2015;39(1):91-6. https://doi.org/10.1016/j.canep.2014.10.012.
Adrada JC, Calambas F, Díaz JE, Delgado DO, Sierra CH. Características sociodemográficas y clínicas en una población con cáncer gástrico en el Cauca, Colombia. Rev Col Gastroenterol. 2008;23(4) 309-14.
Martínez J, Garzón M, Lizarazo J, Marulanda JC, Molano JC, Rey M, et al. Características de los pacientes con cáncer gástrico del departamento de Cundinamarca remitidos al Hospital universitario de la Samaritana entre los a-os 2004-2009. Rev Col Gastroenterol. 2010;25(4): 344-48.
Gaviria A, Cubillos L. Costos médicos directos en el tratamiento del cáncer gástrico en los estadios 0 a IIIB en pacientes adultos en Colombia. Colombia: UDCA; 2015.
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
